SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company ...

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into ...

∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. IARS2, isoleucyl-tRNA synthetase 2; PDAC, pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of ...

Aminoacyl tRNA synthetases picked up new protein domains that participate ... growth factor A (VEGF-A), preventing over-vascularization. In addition, a combo synthetase for glutamic acid and proline, ...

During tRNA development, the researchers identified 12 highly active tRNA synthetase/tRNA pairs in Escherichia coli that can add canonical and noncanonical amino acids. Then, Badran’s team used ...

Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent ...

In order to facilitate these applications, we have: 1) Developed new aminoacyl-tRNA synthetase/tRNA platforms that enable site-specific incorporation of previously inaccessible structural classes of ...

At aTyr, we’re on a mission to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Our lead therapeutic candidate, efzofitimod, is a first-in-class biologic ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology ...

Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent ...

The publication presents the foundational science, detailed preclinical studies and discovery work behind efzofitimod, an immunomodulator derived from a splice variant of histidyl-tRNA synthetase ...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl ...